# Nuvalent (NUVL) shares are higher on news GSK agreed to buy Nuvalent for $10.6 billion.

*biotech, business · news · 2026-06-09 · MarketScreener*

## Key points

- GSK is acquiring Nuvalent for $10.6 billion to expand its lung cancer treatment portfolio.
- Nuvalent's share price rose following the acquisition agreement with GSK.
- JM Smucker's fourth-quarter profits exceeded Wall Street expectations due to higher product prices.
- Vail Resorts lowered its full-year net income guidance, citing challenging weather in the western US.

On this episode of Stock Movers with Alexis Christoforous: - Nuvalent (NUVL) shares are higher on news GSK agreed to buy Nuvalent for $10.6 billion, securing a US biotech firm developing treatments for lung cancer. - JM Smucker (SJM) shares are on the move after it posted fourth-quarter profits that beat Wall Street expectations as higher prices helped boost the packaged food company. - Vail Resorts (MTN) is dropping after the ski resort operator cut its net income guidance for the full year, attributing the reduction to "historically challenging" weather conditions in the western US. The guidance missed the average analyst estimate. Bloomberg videos, provided by MT Newswires

**Companies:** GSK, Nuvalent, JM Smucker, Vail Resorts
**Countries:** United States, United Kingdom

[Read the full story on MarketScreener](https://www.marketscreener.com/news/jm-smucker-moves-on-profit-beat-vail-resorts-down-on-full-year-guidance-cut-stock-movers-ce7f5cdad880f526)

---

Canonical: https://newsio.io/n/2465056d-87e2-4f21-9cd3-0c8fa546e96a/nuvalent-nuvl-shares-are-higher-on-news-gsk-agreed-to-buy-nuvalent-for-10-6-bill
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works